FDA Permits Marketing of Clinical Decision Support Software for Alerting Providers of a Potential Stroke in Patients

FDAToday, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.

A stroke is a serious medical condition that requires emergency care and can cause lasting brain damage, long-term disability or even death. A stroke occurs if the flow of oxygen-rich blood to a portion of the brain is blocked, also known as an occlusion. According to the Centers for Disease Control and Prevention, stroke is the fifth leading cause of death in the U.S. and is a major cause of serious disability for adults. About 795,000 people in the U.S. have a stroke each year.

"Strokes can cause serious and irreversible damage to patients. The software device could benefit patients by notifying a specialist earlier thereby decreasing the time to treatment. Faster treatment may lessen the extent or progression of a stroke," said Robert Ochs, Ph.D., acting deputy director for radiological health, Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

The Viz.AI Contact application is a computer-aided triage software that uses an artificial intelligence algorithm to analyze images for indicators associated with a stroke. Artificial intelligence algorithms are a type of clinical decision support software that can assist providers in identifying the most appropriate treatment plan for a patient’s disease or condition. The FDA is currently creating a regulatory framework for these products that encourages developers to create, adapt and expand the functionalities of their software to aid providers in diagnosing and treating diseases and conditions.

The Viz.AI Contact application is designed to analyze CT images of the brain and send a text notification to a neurovascular specialist if a suspected large vessel blockage has been identified. The algorithm will automatically notify the specialist during the same time the first-line provider is conducting a standard review of the images, potentially involving the specialist sooner than the usual standard of care in which patients wait for a radiologist to review CT images and notify a neurovascular specialist. The notification can be sent to a mobile device, such as a smart phone or tablet, but the specialist still needs to review the images on a clinical workstation.

The Viz.AI Contact application is intended to be used by neurovascular specialists, such as vascular neurologists, neuro-interventional specialists or other professionals with similar training. The application is limited to analysis of imaging data and should not be used as a replacement of a full patient evaluation or solely relied upon to make or confirm a diagnosis.

The company submitted a retrospective study of 300 CT images that assessed the independent performance of the image analysis algorithm and notification functionality of the Viz.AI Contact application against the performance of two trained neuro-radiologists for the detection of large vessel blockages in the brain. Real-world evidence was used with a clinical study to demonstrate that the application could notify a neurovascular specialist sooner in cases where a blockage was suspected.

The Viz.AI Contact application was reviewed through the De Novo premarket review pathway, a regulatory pathway for some new types of medical devices that are low to moderate risk and have no legally marketed predicate device to base a determination of substantial equivalence. This action also creates a new regulatory classification, which means that subsequent computer-aided triage software devices with the same medical imaging intended use may go through the FDA's premarket notification (510 (k)) process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The FDA permitted marketing of the Contact application to Viz.AI.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Most Popular Now

Researchers Apply Computing Power to Tra…

Princeton researchers have developed a new computational method that increases the ability to track the spread of cancer cells from one part of the body to another. This migration of...

Philips Powers First Tele-Intensive Care…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Japan-based Showa University announced the launch of Japan's first telemedicine intensive care (eICU) program at Showa University...

Open Call SC1-DTH-10-2019-2020: Digital …

Digital solutions supporting a continuum of care across a range of health and care services can relieve the pressure on governments to provide more cost-effective health and care systems by...

AI and Radar Technologies could Help Dia…

People with diabetes could be able to monitor their blood sugar without drawing blood using a system now being developed at the University of Waterloo. In a recent study, researchers...

Bad Habits that Lead to Cancer, Chronic …

Does this sound like someone you know? He or she spends too much time in front of screens, gets little exercise and eats a diet high in fat and low...

Private Healthcare Data to be Captured b…

An initiative has been launched to ensure private healthcare data is recorded in the same way as NHS data in England, with the aim of improving consistency across the system...

Research Finds Three Major Failings in s…

In the scramble to bring successful apps for the diagnosis of skin cancer to market there is a concern that a lack of testing is risking public safety, according to...

New Tissue-Imaging Technology could Enab…

A new microscope system can image living tissue in real time and in molecular detail, without any chemicals or dyes, report researchers at the University of Illinois. The system uses...

New Technology Helps to Improve Treatmen…

A new web-based "feedback" technology which allows therapists to accurately monitor how patients with depression are coping has been found to reduce the probability of deterioration during psychological treatment by...

Rapid Zika Detection Test Uses Smartphon…

The Zika virus, which continues to cause microcephaly and other neurological complications in infants whose mothers were infected during pregnancy, remains a public health concern. Investigators from Brigham and Women's...

AAL Market and Investment Report

The AAL Market and Investment Report was commissioned by the Ambient Assisted Living Association and aims to provide a consolidated view of the existing market and investment information in Europe...